4967.T
4967.T
JP3301100008
KOBAYASHI PHARMACEUTICALS
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±25.3% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.2x).

Beta (Market Relation)
0.2x
Defensive
Volatility (5Y p.a.)
25.3% p.a.
5-Year Horizon
Max Drawdown (5Y)
-53.1%
5-Year Horizon
Sharpe Ratio
-0.25
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +37.4%
3 Years 26.6% -29.8% -0 +2.5%
5 Years 25.3% -53.1% -0.25 -3.7%
10 Years 26.8% -62.1% 0.02 +3.1%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 329.7 (Elevated multiple compression risk)
Historical Stress Test: Maximum peak-to-trough drawdown of -62.1% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
4 ISS Score: 4 / 10
Audit Risk
1 ISS Score: 1 / 10
Board Risk
3 ISS Score: 3 / 10
Short Ratio
-
ende